Labetalol Hydrochloride (Monograph)

Drug class: beta-Adrenergic Blocking Agents

Medically reviewed by Drugs.com on Jun 10, 2024. Written by ASHP.

Introduction

Selective α₁- and nonselective β-adrenergic blocking agent (β-blocker).¹ ² ³ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹ ¹⁹ ²¹ ²² ²³ ³²

Uses for Labetalol Hydrochloride

Hypertension

Management of hypertension, alone or in combination with other classes of antihypertensive agents.² ⁴ ²⁵³ ¹²⁰⁰

β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).³³⁷ ⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵¹⁵ ⁵²³ ⁵²⁴ ⁵²⁷ ⁷⁰⁰ ¹²⁰⁰ A 2017 ACC/AHA multidisciplinary hypertension guideline states that β-blockers used for ischemic heart disease that are also effective in lowering BP include bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, and timolol.¹²⁰⁰

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵¹⁵ ¹²⁰⁰ ¹²⁰¹

The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.¹²⁰⁰ (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults 1200
Category	SBP (mm Hg)		DBP (mm Hg)
Normal	<120	and	<80
Elevated	120–129	and	<80
Hypertension, Stage 1	130–139	or	80–89
Hypertension, Stage 2	≥140	or	≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.¹²⁰⁰ However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.⁵⁰¹ ⁵⁰³ ⁵⁰⁴ ⁵⁰⁵ ⁵⁰⁶ ⁵⁰⁷ ⁵⁰⁸ ⁵¹⁵ ⁵²³ ⁵²⁶ ⁵³⁰ ¹²⁰⁰ ¹²⁰¹ ¹²⁰⁷ ¹²⁰⁹ ¹²²² ¹²²³ ¹²²⁹

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.¹²⁰⁰ In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.¹²⁰⁰ These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.¹²⁰⁰ ¹²⁰² ¹²¹⁰

Other hypertension guidelines generally have based target BP goals on age and comorbidities.⁵⁰¹ ⁵⁰⁴ ⁵³⁶ Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients⁵⁰¹ ⁵⁰⁴ compared with those recommended by the 2017 ACC/AHA hypertension guideline.¹²⁰⁰

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.¹²²² ¹²²³ ¹²²⁴ ¹²²⁹

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.¹²⁰⁰ ¹²²⁰

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.¹²⁰⁰ ¹²⁰⁷ ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.¹²⁰⁰

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).¹²⁰⁰

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.¹²⁰⁰

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.¹²⁰⁰ Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.⁵⁰² ¹²⁰⁰

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.¹²⁰⁰ Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.¹²⁰⁰

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.³²⁷ ³³⁴ ³³⁵ ⁵⁰¹ ⁵⁰⁴ ¹²⁰⁰ However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.⁵⁰⁰

Recommended by ACOG and other experts as an appropriate drug of choice in pregnant women who require antihypertensive therapy.²⁹⁸ ⁵⁰² ⁵⁴⁰

Severe Hypertension and Hypertensive Crisis

Used parenterally for immediate BP reduction in severe hypertension or hypertensive emergency;¹ ³ ⁷ ⁸ ¹⁴ ¹⁵ ¹⁶ ⁵¹ ⁵² ⁵³ ⁷³ ⁷⁹ ⁹³ ⁹⁴ ¹⁵² ¹⁹⁷ ¹⁹⁸ ²⁰⁹ ²¹⁰ ²³⁵ ²³⁶ ²⁴⁰ ⁵⁰² ⁵⁴² ¹²⁰⁰ generally suitable for most hypertensive emergencies except when acute cardiac failure is present.²³⁹ ¹²⁰⁰

One of several recommended parenteral agents for use in the hospital setting to urgently lower BP in severely hypertensive pregnant women, including those with preeclampsia^{† [off-label]} or eclampsia^{† [off-label]}.²⁹⁸ ³³⁸ ⁵⁴⁰ ¹²⁰⁰

Has been used for rapid reduction of BP in children and adolescents^{† [off-label]} with acute severe hypertension^{† [off-label]} and life-threatening symptoms.¹¹⁵⁰

Pheochromocytoma

Has been used alone in patients with pheochromocytoma to control hypertension and symptoms resulting from excessive β-receptor stimulation.⁵¹ ⁸⁵ ¹⁸¹ ¹⁸² ¹⁸³ ¹⁸⁴ However, some clinicians caution against use unless pretreatment with α-adrenergic blocking agents (e.g., IV phentolamine) has occurred.⁷ May be more effective when tumors predominantly secrete epinephrine rather than norepinephrine, and with sustained rather than paroxysmal hypertension.⁸⁵ (See Pheochromocytoma under Cautions.)

Controlled Hypotension during Anesthesia

Treatment to produce controlled hypotension during anesthesia^{† [off-label]} to reduce bleeding resulting from surgical procedures.⁷ ¹⁸³ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵

Chronic Stable Angina

Long-term management of chronic stable angina pectoris^†.⁷ ¹⁷ ¹⁸ ¹²⁷

β-Blockers are recommended as first-line anti-ischemic drugs in most patients with chronic stable angina; despite differences in cardioselectivity, intrinsic sympathomimetic activity, and other clinical factors, all β-blockers appear to be equally effective for this use.¹¹⁰¹

Tetanus

Management of sympathetic overactivity syndrome associated with severe tetanus^†.¹⁹⁶ ²⁰⁰ ²⁰¹ ²⁰²

Labetalol Hydrochloride Dosage and Administration

General

If long-term therapy is discontinued, gradually reduce dosage over a period of 1–2 weeks.² ⁴ ²⁹³ (See Abrupt Withdrawal of Therapy under Cautions.)

BP Monitoring and Treatment Goals

Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.¹²⁰⁰
If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.¹²¹⁶
If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).¹²⁰⁰ ¹²¹⁶ Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.¹²⁰⁰ ¹²¹⁶

Severe Hypertension and Hypertensive Crisis

Adjust dosage according to the severity of hypertension and the patient’s supine BP response and tolerance.⁶⁰⁰
Initial goal of IV therapy in adults without a compelling indication is to reduce SBP by ≤25% within 1 hour, followed by further BP reduction if stable to 160/100 or 160/110 mm Hg within the next 2–6 hours; avoid excessive declines in pressure that could precipitate renal, cerebral, or coronary ischemia.⁵⁴² ¹²⁰⁰ If this BP is well tolerated and the patient is clinically stable, may implement further gradual reductions toward normal BP in the next 24–48 hours.¹²⁰⁰
Adults with severe preeclampsia or eclampsia or pheochromocytoma crisis: Reduce SBP to <140 mm Hg during the first hour.¹²⁰⁰
Adults with aortic dissection: Reduce SBP to <120 mm Hg within the first 20 minutes.¹²⁰⁰
Children and adolescents: Some experts suggest reducing BP by ≤25% of the planned reduction over the first 8 hours.¹¹⁵⁰

Administration

Administer orally,² ⁴ ⁷ ⁸ ¹⁹ ²³ ⁴⁷ ⁴⁹ by direct IV injection, or by continuous IV infusion.¹ ³ ⁷ ¹⁹ ²³ ⁵¹ ⁵² ⁵³ ⁷³ ⁷⁹ ⁹³ ⁹⁴ ²¹⁰

Oral Administration

Usually administered in 2 divided doses daily.² ⁴ If adverse effects (e.g., nausea, dizziness) occur and are intolerable (particularly with dosages ≥1.2 g daily), administration in 3 divided doses daily may improve patient tolerance and/or facilitate dosage titration.² ⁴

Also has been administered as an extemporaneously compounded oral suspension using the commercially available tablets.¹³

Standardize 4 Safety

Standardized concentrations for an oral compounded liquid formulation of labetalol have been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care.³⁴² Because recommendations from the S4S panels may differ from the manufacturer’s prescribing information, caution is advised when using concentrations that differ from labeling, particularly when using rate information from the label.³⁴² For additional information on S4S (including updates that may be available), see [Web].

Table 2: Standardize 4 Safety Standards for Labetalol Hydrochloride Compounded Oral Liquid13342
Concentration Standard
40 mg/mL

IV Administration

Administer by slow, direct IV injection or by slow, continuous IV infusion.¹ ³ ⁷ ¹⁹ ²³ ⁵¹ ⁵² ⁵³ ⁷³ ⁷⁹ ⁹³ ⁹⁴ ²¹⁰

Labetalol injection is intended for use in hospitalized patients.¹

Patients must be kept in a supine position during and for 3 hours after IV administration since symptomatic orthostatic hypotension is likely to occur if patients are tilted upward or allowed to assume an upright position.¹ ³ (See Hypotension under Cautions.)

Dilution

For IV infusion, dilute labetalol injection to an appropriate concentration in a compatible IV infusion solution (e.g., add 200 mg of the drug to 160 mL of 5% dextrose injection to provide a solution containing 1 mg/mL).¹ ³

Rate of Administration

Administer repeat doses by slow, direct IV injection over a 2-minute period at intervals of 10 minutes.¹ ³ ⁵³ ⁷³ ⁷⁹ ⁹⁴ ²⁹⁸ ¹²⁰⁰

Administer diluted solutions by slow, continuous IV infusion¹ ³ ⁵¹ ⁷³ ²¹⁰ with a controlled-infusion device to facilitate a desired rate of infusion.¹ ³

Standardize 4 Safety

Standardized concentrations for labetalol have been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care.³³⁹ ³⁴⁰ Because recommendations from the S4S panels may differ from the manufacturer’s prescribing information, caution is advised when using concentrations that differ from labeling, particularly when using rate information from the label.³³⁹ ³⁴⁰ For additional information on S4S (including updates that may be available), see[Web].³³⁹ ³⁴⁰

Table 3: Standardize 4 Safety Continuous IV Infusion Standard Concentrations for Labetalol Hydrochloride339340
Patient Population	Concentration Standards	Dosing Units
Adults	1 mg/mL	mg/min
	5 mg/mL
Pediatric patients (<50 kg)	1 mg/mL	mg/kg/hour
	5 mg/mL

Dosage

Available as labetalol hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Hypertension†

Oral

Some experts have recommended an initial dosage of 1–3 mg/kg daily given in 2 divided doses.³³³ Increase dosage as necessary up to a maximum of 10–12 mg/kg or 1.2 g daily given in 2 divided doses.³³³

Severe Hypertension†

Rapid Reduction of BP†

IV Injection

Children and adolescents: 0.2–1 mg/kg up to maximum of 40 mg per dose by direct IV injection.¹¹⁵⁰

IV Infusion

Alternatively, 0.25–3 mg/kg per hour by continuous IV infusion.¹¹⁵⁰

Adults

Hypertension

Oral

Initially, 100 mg twice daily, either alone or in combination with a diuretic.² ⁴ ²⁹³

Adjust dosage in increments of 100 mg twice daily every 2 or 3 days until optimum BP response is achieved.² ⁴

For maintenance, manufacturers recommend a usual dosage of 200–400 mg twice daily.² ⁴ Manufacturers state that some adults with severe hypertension may require up to 1.2–2.4 g daily in 2 or 3 divided doses.² ⁴ ^a

Some experts recommend a usual range of 100–400 mg twice daily.¹²⁰⁰ Rationale for lower dosage range is that it may be preferable to add another drug rather than continue to increase dosage.³³²

Adjustment of labetalol dosage may be necessary when diuretic is initiated in a patient already receiving labetalol; optimum maintenance dosage is usually lower.² ⁴

When transferring from other antihypertensive agents, start with usual initial labetalol dosage and gradually decrease dosage of the existing regimen.² ⁴

Severe Hypertension and Hypertensive Crisis

IV Injection

Manufacturer recommends initial dose of 20 mg by slow (over 2 minutes), direct IV injection.⁶⁰⁰ Alternatively, some experts recommend initial dosage of 0.3–1 mg/kg (maximum 20 mg) by slow, direct IV injection every 10 minutes.¹²⁰⁰

Higher initial doses (e.g., 1–2 mg/kg) have been administered,⁵¹ ⁵⁵ ²³⁵ but the 20-mg dose is recommended to minimize adverse effects and the risks associated with too rapid reduction in BP.²³ ⁵³ ⁷⁹

May give additional doses of 40 or 80 mg⁶⁰⁰ at 10-minute intervals until the desired supine BP is achieved or up to a total cumulative dose of 300 mg.⁷ ¹⁹ ⁵³ ⁷³ ⁷⁹ ⁹⁴ ²⁷⁴ ²⁹⁸ ⁶⁰⁰

IV Infusion

As an alternative to direct IV injection, manufacturer recommends initial rate of 2 mg/minute by continuous IV infusion; adjust rate according to the BP response.⁶⁰⁰

Some experts recommend initial IV infusion rate of 0.4–1 mg/kg per hour; increase rate as needed up to 3 mg/kg per hour.¹²⁰⁰

The usual effective, cumulative dose is 50–200 mg; up to 300 mg may be required.⁶⁰⁰ ¹²⁰⁰

Progressive, incremental IV infusion regimen^† (i.e., infusing 20, 40, 80, and 160 mg/hour for 1 hour at each dose level, or until the desired BP is achieved) has been used, and may result in more gradual BP reduction, minimizing adverse effects compared with repeated IV injections of the drug.²¹ ⁵¹ ¹⁹⁷ Controlled comparisons of various IV administration methods are not available.

Oral (following IV dosage)

Discontinue IV therapy and initiate oral labetalol therapy (with tablets) when the supine DBP begins to increase.⁶⁰⁰

Initially 200 mg, followed in 6–12 hours by an additional dose of 200 or 400 mg, depending on the BP response.⁶⁰⁰

If necessary, oral dosage may be increased in usual increments at 1-day intervals while the patient is hospitalized (dosage range: 400–2400 mg daily administered in 2 or 3 divided doses).⁶⁰⁰

Follow the usual oral dosage recommendations for subsequent outpatient dosage titration or maintenance dosing.⁶⁰⁰

Severe Hypertension During Pregnancy (e.g., Preeclampsia†)

IV Injection

Initially, 10–20 mg by direct IV injection, followed by 20–80 mg every 20–30 minutes as needed for a maximum cumulative dose of 300 mg.²⁹⁸

IV Infusion

As an alternative to direct IV injection, some experts recommend continuous IV infusion of 1–2 mg/minute.²⁹⁸

Prescribing Limits

Pediatric Patients

Hypertension

Oral

Maximum 10–12 mg/kg or 1.2 g daily.³³³

Severe Hypertension†

IV Injection

Children and adolescents: Maximum 40 mg per dose.¹¹⁵⁰

Adults

Hypertension

Oral

Maximum titration increment of 200 mg twice daily.^a

Severe Hypertension and Hypertensive Crisis

IV

Maximum cumulative dose of 300 mg.¹ ³ ⁷ ¹⁹ ⁵³ ⁷³ ⁷⁹ ⁹⁴ ²⁷⁴ ²⁹⁸

Severe Hypertension During Pregnancy (e.g., Preeclampsia†)

IV

Maximum cumulative dose of 300 mg.²⁹⁸

Special Populations

Hepatic Impairment

Dosage reduction may be necessary, but specific data are currently not available.⁷ ³⁹

Renal Impairment

No dosage adjustment required in patients with mild to moderate renal impairment.⁶⁰ ¹⁴⁶ ¹⁴⁷ ²³⁹ In patients with severe renal impairment (i.e., Cl_cr <10 mL/minute) undergoing dialysis, once-daily dosing may be adequate.²⁴¹

Geriatric Patients

Oral

Adjustment in initial dosage not required.^a Maintenance dosage requirements are lower in most geriatric patients; 100–200 mg twice daily usually required.⁴ ^a ⁴

Cautions for Labetalol Hydrochloride

Contraindications

Obstructive airway disease (e.g., bronchial asthma).¹ ² ³ ⁴ ³¹¹
Overt cardiac failure.¹ ² ³ ⁴ ³¹¹
Heart block greater than first degree.¹ ² ³ ⁴ ³¹¹
Cardiogenic shock.¹ ² ³ ⁴ ³¹¹
Severe bradycardia.¹ ² ³ ⁴ ³¹¹
Other conditions associated with severe and prolonged hypotension.¹ ³ ⁴ ²⁴⁷
Known hypersensitivity to labetalol or any ingredient in the formulation.¹ ³ ⁴ ²⁴⁷

Warnings/Precautions

Warnings

Hepatic Effects

Rarely, jaundice, hepatitis, severe hepatocellular injury, and elevated liver function test results have occurred; usually reversible following discontinuance,¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸ however, hepatic necrosis and death have been reported.¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸ ²⁵⁴ ²⁵⁵ ²⁷⁵ ²⁷⁶

Discontinue immediately if jaundice or laboratory evidence of hepatic injury occurs.¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸

Perform liver function tests at the first signs or symptoms of liver dysfunction (e.g., pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness, flu-like syndrome).¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸

Cardiac Failure

Possible precipitation of heart failure.¹ ² ³ ⁴ ⁷ Use contraindicated in patients with overt heart failure;¹ ² ³ ⁴ may use cautiously in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).¹ ² ³ ⁴ Use with caution in patients with inadequate cardiac function.¹ ² ³ ⁴ ⁷

Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs and symptoms of impending cardiac failure occur; if cardiac failure continues, discontinue therapy, gradually if possible.¹ ² ³ ⁴

Abrupt Withdrawal of Therapy

Abrupt withdrawal may exacerbate angina symptoms or precipitate MI in patients with CAD.¹ ² ³ ⁴ Avoid abrupt discontinuance.² ⁴ Gradually decrease dosage over a period of 1–2 weeks, particularly in patients with ischemic heart disease and monitor patients carefully.¹ ² ³ ⁴ If exacerbation of angina occurs or acute coronary insufficiency develops, reinstitute therapy promptly, at least temporarily, and initiate appropriate measures for the management of unstable angina pectoris.¹ ² ³ ⁴

Labetalol may be less likely than pure β-adrenergic blocking agents to produce adverse cardiovascular withdrawal reactions (e.g., angina, rebound hypertension) following abrupt withdrawal;⁹ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁷ ⁷⁸ ¹⁶⁴ angina pectoris has not been reported to date following discontinuance of labetalol.¹ ² ³ ⁴

Bronchospastic Disease

Possible inhibition of bronchodilation produced by endogenous catecholamines; use generally not recommended in patients with bronchospastic disease.² ⁴

May use oral labetalol with caution in patients with nonallergic bronchospasm (e.g., chronic bronchitis, emphysema) who do not respond to or cannot tolerate other hypotensive agents;² ⁴ use smallest effective dose to minimize inhibition of endogenous or exogenous β-adrenergic agonist activity.² ⁴

Do not use IV labetalol in patients with nonallergic bronchospasm at the usual therapeutic doses; has not been studied adequately.¹ ³

Pheochromocytoma

Use with caution in patients with pheochromocytoma;¹ ² ³ ⁴ ¹⁸⁶ ¹⁸⁷ oral labetalol may induce paradoxical hypertensive crisis.⁷ ¹⁸⁶ ¹⁸⁷ ²⁰³ Use not recommended unless pretreatment with α-adrenergic blocking agents (e.g., IV phentolamine) has occurred.⁷

Employ appropriate methods for determining urinary catecholamines if used in known or suspected pheochromocytoma.¹ ² ³ ⁴ (See Specific Drugs and Laboratory Tests under Interactions.)

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, BP changes),¹ ² ³ ⁴ impaired glucose tolerance, delayed rate of recovery of blood glucose concentration following drug-induced hypoglycemia, altered hemodynamic response to hypoglycemia (possibly resulting in exaggerated hypertensive response), and impaired peripheral circulation.²¹¹ ²¹²

Use with caution in patients with diabetes mellitus;¹ ² ³ ⁴ dosage adjustment of the hypoglycemic agent may be necessary.¹ ² ³ ⁴

Major Surgery

Severe, protracted hypotension and difficulty in restarting or maintaining a heart beat have occurred during surgery in some patients receiving β-adrenergic blocking agents;¹ ² ³ ⁴ however, withdrawal of β-adrenergic blocking agent prior to major surgery is controversial.¹ ² ³ ⁴

Effect of labetalol’s α-adrenergic activity in patients undergoing major surgery has not been evaluated,¹ ² ³ ⁴ but several deaths have been reported with the use of the injection during surgery, including when used to control bleeding.¹ ³

Synergistic hypotensive response occurs with concomitant use of IV labetalol and halothane anesthesia.¹ ² ³ ⁴ ¹⁸³ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ (See Specific Drugs and Laboratory Tests under Interactions.)

Severely Elevated BP

Use caution when reducing severely elevated BP.¹ ³

Use IV labetalol in hospitalized patients,¹ ³ and achieve the desired reduction over longest period of time compatible with the patient’s clinical status.¹ ³

Avoid rapid or excessive reductions in SBP or DBP.¹ ³

Serious adverse effects (e.g., cerebral infarction, optic nerve infarction, angina, and ischemic changes in the ECG)⁵¹ ⁷⁹ ¹⁹⁷ have been reported when severely elevated BP was reduced over several hours to up to 1 or 2 days with other hypotensive agents.³¹¹

General Precautions

Hypotension

Orthostatic hypotension associated with loss of consciousness reported occasionally following IV administration⁵¹ ⁵⁴ ⁵⁵ ¹³² and rarely following oral administration.² ⁴ Symptomatic orthostatic hypotension is likely to occur if supine patients are tilted upward or allowed to assume the upright position within 3 hours following IV administration.¹ ³

If hypotension occurs, place the patient in Trendelenburg’s position, administer IV fluids, and/or temporarily discontinue administration of the drug.⁵¹ ⁷⁹ ⁹⁴ ¹⁹⁷

Patients should remain supine during and for up to 3 hours after IV administration.¹ ³ Establish patient’s ability to tolerate an upright position before any ambulation (e.g., use of toilet facilities) is permitted; advise patient on how to proceed gradually to become ambulatory and observe at the time of initial ambulation.¹ ³

Laboratory Tests

Monitor laboratory parameters at regular intervals in patients receiving long-term oral therapy.² ⁴

Routine laboratory tests are usually not required before or after IV administration.¹ ³

In patients with concomitant illnesses (e.g., impaired renal function), perform appropriate tests to monitor these conditions.¹ ² ³ ⁴

Possible Prescribing and Dispensing Errors

Ensure accuracy of prescription; similarity in spelling of labetalol hydrochloride and Lamictal (lamotrigine, an anticonvulsant agent) has resulted in dispensing errors.³¹⁹ ³²⁰ Errors may be associated with serious adverse events (e.g., status epilepticus, serious lamotrigine rash) in patients receiving the wrong drug.³¹⁹ ³²⁰

History of Anaphylactic Reactions

Possible increased reactivity to a variety of allergens;¹ patients may be less responsive to usual doses of epinephrine used to treat anaphylactic reactions.¹ ³ ⁴

Other Precautions

Shares the toxic potentials of β-adrenergic and postsynaptic α₁-adrenergic blocking agents;¹ ² ³ ⁴ ⁷ ⁸ ⁹ observe the usual precautions of these agents.¹ ² ³ ⁴ ⁷

Specific Populations

Pregnancy

Category C.¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸ ^a

Lactation

Distributed into milk.¹ ² ³ ⁴ ⁶ ⁷ ⁶⁴ ⁶⁸ ⁶⁹ Caution if used in nursing women.¹ ² ³ ⁴

Pediatric Use

Safety and efficacy not fully established;¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸ however, some experts have recommended dosages for hypertension based on clinical experience.¹¹⁵⁰

Geriatric Use

Orthostatic symptoms (e.g., orthostatic hypotension, dizziness, lightheadedness) are more likely in geriatric individuals than in younger adults; caution geriatric patients about the possibility of such symptoms.⁴

A lower maintenance dosage may be required because of reduced elimination in geriatric patients.⁴ (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Use with caution; metabolism of the drug may be decreased.¹ ² ³ ⁴ ⁷ ³⁹ ²⁴⁷ ²⁴⁸ (See Special Populations under Pharmacokinetics.)

Renal Impairment

Elimination half-life may be increased in patients with severe renal impairment undergoing dialysis; once-daily dosing may be possible in these patients.²⁴¹ (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Symptomatic orthostatic hypotension,¹ ² ³ ⁴ ⁷ ⁸ ⁹ ¹⁹ ²³ ⁴⁶ ⁵¹ ⁵⁴ ⁵⁵ ⁷⁹ ⁸¹ ⁸³ ⁸⁸ ⁹¹ ⁹⁴ ⁹⁶ ¹⁰⁰ ¹⁰⁸ ¹²² ¹²⁹ ¹³² ¹⁵⁸ ¹⁵⁹ ²⁴⁷ ²⁴⁸ dizziness¹ ² ³ ⁴ ⁸ ²³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁹ ⁸⁰ ⁸¹ ⁸² ⁸⁸ ⁹⁰ ¹⁵⁸ ¹⁵⁹ or lightheadedness,²³ ⁵¹ ⁵³ ⁸⁵ fatigue,¹ ² ³ ⁴ ²³ ⁷⁵ ⁷⁶ ⁷⁸ ⁸⁷ ¹⁵⁹ nausea,¹ ² ³ ⁴ ⁷ ⁸ ¹⁹ ²³ ⁵¹ ⁵³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁸ ⁷⁹ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁷ ⁹⁰ ⁹³ ⁹⁴ ¹⁵⁸ ¹⁵⁹ ²⁴⁷ ²⁴⁸ dyspepsia.¹ ² ³ ⁴ ⁷ ⁸ ²³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁹ ⁸² ⁸³ ⁹³ ⁹⁴ ¹⁵⁸ ¹⁵⁹ ²⁴⁷ ²⁴⁸

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Test	Interaction	Comments
β-Adrenergic agonists	Labetalol may antagonize bronchodilating effects¹ ² ³ ⁴	Greater than usual dosages of β-adrenergic agonist bronchodilators may be required¹ ² ³ ⁴
Calcium-channel blocking agents (e.g., verapamil, diltiazem)	Possible additive therapeutic²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶¹ ²⁶² ²⁶³ ²⁶⁴ ²⁶⁵ ²⁶⁷ ²⁶⁸ ²⁶⁹ ²⁷⁰ ²⁷¹ ²⁷² ²⁷³ and adverse effects²⁵⁷ ²⁶¹ ²⁶⁴ ²⁶⁶ ²⁶⁷ ²⁶⁸ ²⁷¹ ²⁷² ²⁷³	Use concomitantly with caution¹ ³ ⁴ ²⁴⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶¹ ²⁶⁴ ²⁶⁶ ²⁶⁸ ²⁷¹ ²⁷² ²⁷³ ²⁹⁰ ²⁹¹
Cimetidine	Absolute bioavailability of oral labetalol substantially increased, possibly via enhanced absorption or decreased first-pass hepatic metabolism ¹ ² ³ ⁴ ¹⁸⁰ ²²⁹	Carefully adjust labetalol dosage for optimal BP control with concomitant use¹ ² ³ ⁴ ²²⁹
Diuretics	Increased hypotensive effect ² ⁴ ⁷ ⁸ ⁹ ¹⁵ ¹⁹ ⁷² ⁷⁶ ⁷⁷ ⁷⁸ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁵ ⁸⁷ ⁹⁰ ⁹¹ ⁹⁶ ⁹⁷ ⁹⁹ ²³¹ ²³⁴	Usually used to therapeutic advantage; careful dosage adjustments recommended² ⁴ ⁷ ⁸ ⁹ ¹⁵ ¹⁹ ⁷² ⁷⁶ ⁷⁷ ⁷⁸ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁵ ⁸⁷ ⁹⁰ ⁹¹ ⁹⁶ ⁹⁷ ⁹⁹ ²³¹ ²³⁴
Glutethimide (no longer commercially available in the US)	Absolute bioavailability of oral labetalol decreased, possibly by increasing first-pass hepatic metabolism ²²⁹	Carefully adjust labetalol dosage for optimal BP control with concomitant use²²⁹
Halothane	Synergistic hypotensive effect; ¹⁸³ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ may result in large reduction in cardiac output and increase in central venous pressure¹ ² ³ ⁴ ¹⁸³ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵	Adjust halothane concentration to control the degree and duration of hypotension;¹⁸³ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ to minimize the risk of excessive hypotension, inspired halothane concentrations of ≥3% should not be used¹ ² ³ ⁴ Inform anesthesiologist if labetalol therapy is continued in a patient undergoing major surgery¹ ² ³ ⁴
Mibefradil (no longer commercially available in the US)	Slowing or complete suppression of SA node activity, with slow ventricular rates²⁹⁰ ²⁹¹
Nitroglycerin	Possible additive hypotensive effects¹ ² ³ ⁴ and antagonism of the reflex tachycardia produced by nitroglycerin¹ ² ³ ⁴
Tricyclic antidepressants	Possible increased incidence of tremor ¹ ² ³ ⁴
Tests for urinary catecholamines	Labetalol metabolites in urine may result in false-positive elevations of urinary free²¹⁶ and total²¹⁷ catecholamines, metanephrine, normetanephrine, and 3-methoxy-4-hydroxymandelic acid (vanillylmandelic acid, VMA) measured by fluorometric or photometric methods¹ ² ³ ⁴ ²¹⁶ ²¹⁷ ²¹⁸ ²⁴⁸	When screening labetalol-treated patients suspected of having pheochromocytoma or when evaluating labetalol-treated patients with the tumor, use specific assay methods such as high-performance liquid chromatography (HPLC) with solid phase extraction¹ ² ³ ⁴ ²¹⁸ ²⁴⁸ ²⁵² to determine concentrations of catecholamines or their metabolites¹ ² ³ ⁴ ²¹⁶ ²¹⁷ ²¹⁸ ²⁴⁸

Labetalol Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Rapidly and almost completely absorbed (i.e., 90–100%) from the GI tract following oral administration.² ⁴ ⁵ ⁶ ⁷ ⁸ ¹⁰ ³⁴ ⁵⁸ ⁵⁹

Undergoes extensive first-pass metabolism in the liver and/or GI mucosa.² ⁴ ⁵ ⁶ ⁷ ⁸ ¹⁰ ²³ ³³ ³⁴ ³⁵ ³⁷ ⁴¹ ⁵⁸ Absolute bioavailability is about 25%.² ⁴ ⁵ ⁶ ⁷ ³⁴ ³⁷

Onset

Following oral administration, hypotensive effect is generally apparent within 20 minutes to 2 hours,⁶ ¹⁰ ³⁴ ⁴³ ⁴⁸ ⁵⁶ ⁵⁷ and maximal within 1–4 hours.² ⁴ ⁵ ⁶ ⁷ ³⁴ ⁴³ ⁴⁸ ⁵⁶

Maximum, steady-state BP response with twice-daily dosing occurs within 1–3 days.² ⁴

Following slow, direct IV injection, hypotensive effect is apparent within 2–5 minutes,⁵ ⁶ ⁷ ³³ ⁴⁷ ⁵¹ ⁵² ⁵³ ⁵⁴ ⁵⁵ ²⁴⁰ and usually maximal within 5–15 minutes.¹ ³ ⁵³ ⁵⁴ ⁵⁵ ²⁴⁰

Duration

Dose dependent; about 8–12 or 12–24 hours after a single 200- or 300-mg dose, respectively.² ⁴ ⁵ ⁶ ⁴³ ⁵⁷

Following slow, direct IV injection, the hypotensive effect generally persists for about 2–4 hours,⁶ ⁵³ ⁵⁵ although a longer duration of effect (i.e., up to 24 hours) has been reported in some patients.⁶ ³³ ⁵³ ⁵⁵ ²⁴⁰

Food

Delays absorption,³⁶ but increases absolute bioavailability.² ⁴ ⁵ ⁷ ¹⁰ ³⁶ ³⁷

Special Populations

Relative bioavailability is increased in hepatic impairment.^a ¹ ² ³ ⁴ ⁵ ¹⁰ ³⁹

First-pass metabolism may be reduced and bioavailability substantially increased in geriatric patients.⁷ ¹⁰ ³⁸

Distribution

Extent

Following IV administration, rapidly and widely distributed into the extravascular space.⁵ ⁷ ¹⁰ ³³ ³⁴ ³⁵

In animals, highest concentrations in the lungs, liver, and kidneys;⁵ ⁷ ¹⁰ ⁵⁸ only minimal amounts cross the blood-brain barrier.¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ⁵⁸

Crosses the placenta;¹ ² ³ ⁴ ⁵ ⁶ ⁵⁸ ⁶⁴ ⁶⁵ ⁶⁶ ⁶⁷ ⁷⁰ distributed into milk,¹ ² ³ ⁴ ⁵ ⁶ ⁷ ⁶⁴ ⁶⁸ ⁶⁹ principally as unbound labetalol.⁵

Plasma Protein Binding

Approximately 50%.¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ⁵⁸

Special Populations

In patients with impaired hepatic function, the apparent volume of distribution is decreased.³⁹

Elimination

Metabolism

Following oral administration, extensively metabolized in the liver and possibly in the GI mucosa principally by conjugation with glucuronic acid,¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ⁵⁸ principally to O-alkylglucuronide⁵ and smaller amounts of O-phenylglucuronide and N-glucuronide.⁵ ¹⁰ ⁵⁸

Undergoes extensive first-pass metabolism in the liver and/or GI mucosa.² ⁴ ⁵ ⁶ ⁷ ⁸ ¹⁰ ²³ ³³ ³⁴ ³⁵ ³⁷ ⁴¹ ⁵⁸

Elimination Route

Excreted in feces via biliary elimination (30% within 4 days) and in urine (55–60% within 24 hours), mainly as glucuronide conjugates.¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ⁵⁸ ¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ⁵⁸

Less than 5% of a dose is excreted unchanged in urine.⁷ ¹⁰ ⁵⁸

Half-life

Biphasic⁵ ⁷ ¹⁰ ³³ ³⁵ ⁴³ ⁵⁸ ⁵⁹ or possibly triphasic;¹⁰ ³³ ²⁴¹ terminal half-life averages 2.5–8 hours.¹ ² ³ ⁴ ⁵ ⁷ ¹⁰ ³³ ³⁵ ³⁷ ³⁸ ³⁹ ⁴¹ ⁴³ ⁵⁸ ⁶⁰ ⁶³ Manufacturers specify half-life of 5.5 or 6–8 hours following IV or oral administration, respectively.¹ ² ³ ⁴

Special Populations

Elimination may be reduced and half-life may be slightly increased in geriatric individuals.⁴ ⁷ ¹⁰ ³⁸

Half-life apparently unchanged in individuals with renal¹ ² ³ ⁴ ⁵ ¹⁰ ⁶⁰ ⁷¹ ²³⁹ or hepatic impairment,¹ ² ³ ⁴ ³⁹ but may be increased in patients with severe renal impairment (i.e., Cl_cr <10 mL/minute) undergoing dialysis.²⁴¹

Not appreciably removed (<1% of a dose) by hemodialysis²⁰³ ²⁰⁴ ²⁴¹ ²⁴² or peritoneal dialysis.²⁰³ ²²³ ²⁴¹ ²⁴²

Stability

Storage

Oral

Tablets

Well-closed containers²⁰ at 2–30°C.² ⁴ ⁵ ⁶

Protect tablets in unit-dose packages from excessive moisture.² ⁴ ⁵ ⁶

Parenteral

Injection

2–30°C; protect from light and freezing.¹ ³ ⁵ ⁶

Actions

Competitively blocks adrenergic stimulation of β-receptors within the myocardium (β₁-receptors) and within bronchial and vascular smooth muscle (β₂-receptors) and α₁-receptors within vascular smooth muscle.¹ ² ³ ⁴ ⁷ ⁸ ⁹ ²¹ ²² ²³ ²⁴ ²⁸ ²⁹ ³⁰ ³² ⁴⁴
Has some intrinsic β₂-agonist activity in animals,¹ ² ³ ⁴ ⁷ ³⁰ ⁶² ²²¹ ²²² but exerts little, if any, intrinsic β₁-agonist activity;¹ ² ³ ⁴ ⁷ ⁸ ⁹ ³⁰ ⁶² ¹⁰⁷ does not exhibit intrinsic α-adrenergic agonist activity.⁷ ²⁸ ³⁰
Unlike pure β-adrenergic blocking agents, produces a dose-dependent (at usual doses) decrease in systemic arterial BP and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.¹ ² ³ ⁴ ⁷ ¹¹² ¹¹³ ¹¹⁴
Effectively reduces BP in the standing or supine position, but because of the drug’s α₁-adrenergic blocking activity, the effect on BP is position dependent; labetalol-induced decreases in BP are greater in the standing than in the supine position, and orthostatic hypotension can occur.¹ ² ³ ⁴ ⁷ ⁸ ⁹ ¹¹² ¹¹³ ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹²¹ ¹²² ¹²³ ¹²⁴
Electrophysiologic effects of labetalol are variable and appear to be mediated via the drug’s myocardial β₁-adrenergic blocking activity.¹ ² ³ ⁴ ⁷ ¹¹¹ ²¹⁹ ²²⁰
May decrease conduction velocity through the AV node and increase the atrial effective refractory period (ERP), but the drug appears to have inconsistent effects on SA conduction time and the AV nodal refractory period;¹ ² ³ ⁴ ⁷ ¹¹¹ the decrease in AV nodal conduction velocity produced by labetalol is less than that produced by pure β-adrenergic blocking agents.⁷
Generally has little effect on sinus rate, intraventricular conduction, the His-Purkinje system, or duration of the QRS complex.¹ ² ³ ⁴ ⁷ ¹¹¹

Advice to Patients

Importance of taking medication exactly as prescribed.^a
Importance of not interrupting or discontinuing therapy without consulting clinician; patients should temporarily limit their physical activity when discontinuing therapy.¹ ² ³ ⁴
Importance of patients informing anesthesiologist or dentist about labetalol therapy before undergoing major surgery.¹ ² ³ ⁴
Importance of immediately informing clinician at the first sign or symptom of impending cardiac failure or if any difficulty in breathing occurs.¹ ² ³ ⁴
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.¹ ² ³ ⁴
Advise patients that transient scalp tingling may occur, usually during initiation of labetalol therapy.¹ ² ³ ⁴
Caution geriatric patients about the possibility of orthostatic symptoms (orthostatic hypotension, dizziness, lightheadedness).⁴
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹ ² ³ ⁴ ²⁴⁷ ²⁴⁸
Importance of informing patients of other important precautionary information. (See Cautions.)

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Labetalol Hydrochloride
Routes	Dosage Forms	Strengths	Brand Names
Oral	Tablets, film-coated	100 mg*	Labetalol Hydrochloride Tablets
		200 mg*	Labetalol Hydrochloride Tablets
		300 mg*	Labetalol Hydrochloride Tablets
Parenteral	Injection, for IV use	5 mg/mL*	Labetalol Hydrochloride Injection

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Schering Corporation. Normodyne (labetalol hydrochloride) injection prescribing information (dated 1997 Feb). In: Physicians’ desk reference. 52nd ed. Montvale, NJ: Medical Economical Company Inc; 1998(Suppl A):A280-2.

2. Schering Corporation. Normodyne tablets prescribing information. Kenilworth, NJ; 1990 Apr.

3. Glaxo Wellcome. Hanburys. Trandate (labetalol hydrochloride) injection prescribing information. Research Triangle Park, NC; 1998 Apr.

4. Glaxo Wellcome. Trandate (labetalol hydrochloride) tablets prescribing information. Research Triangle Park, NC; 1998 Jun.

5. Schering Corporation. Normodyne (labetalol HCl) product monograph. Kenilworth, NJ; 1984.

6. Glaxo Inc. Product information form for American Hospital Formulary Service on Trandate. Research Triangle Park, NC; 1984 Aug 24.

7. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983; 3:193-219. https://pubmed.ncbi.nlm.nih.gov/6310529

8. Wallin JD, O’Neill WM. Labetalol: current research and therapeutic status. Arch Intern Med. 1983; 143:485-90. https://pubmed.ncbi.nlm.nih.gov/6338850

9. Michelson EL, Frishman WH. Labetalol: an alpha- and beta-adrenoceptor blocking drug. Ann Intern Med. 1983; 99:553-5. https://pubmed.ncbi.nlm.nih.gov/6137987

10. McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. Clin Pharmacokinet. 1984; 9:157-67. https://pubmed.ncbi.nlm.nih.gov/6370541

11. Weber MA. Beta blockers in the initial therapy of hypertension. Drug Ther. 1980; 10(11):77-80.

12. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.

13. Allen LV Jr, Erickson MA III. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996; 53:2304-9.

14. Pearson RM, Griffith DNW, Woollard M et al. Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: preliminary findings. Br J Clin Pharmacol. 1979; 8(Suppl 2):195-8S.

15. MacCarthy EP, Frost GW, Stokes GS. Labetalol in hypertensive emergencies. Med J Aust. 1978; 1:399-400. https://pubmed.ncbi.nlm.nih.gov/672732

16. Yeung CK, Thomas GW, Whitworth JA et al. Comparison of labetalol, clonidine and diazoxide intravenously administered in severe hypertension. Med J Aust. 1979; 2:499-500. https://pubmed.ncbi.nlm.nih.gov/522807

17. Quyyumi AA, Wright C, Mockus L et al. Effects of combined alpha and beta adrenoceptor blockade in patients with angina pectoris. A double blind study comparing labetalol with placebo. Br Heart J. 1985; 53:47-52. https://pubmed.ncbi.nlm.nih.gov/3881105

18. Upward JW, Akhras F, Jackson G. Oral labetalol in the management of stable angina pectoris in normotensive patients. Br Heart J. 1985; 53:53-7. https://pubmed.ncbi.nlm.nih.gov/3917674

19. Anon. Labetalol for hypertension. Med Lett Drugs Ther. 1984; 26:83-5. https://pubmed.ncbi.nlm.nih.gov/6147747

20. USP DI Update. No. 1. Labetalol. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1985:5-8.

21. Robertson JIS. Labetalol: the nineteen-eighties. Br J Clin Pharmacol. 1982; 13(Suppl 1):137-41S.

22. Conner CS. Labetalol: an alpha- and beta-blocker. Drug Intell Clin Pharm. 1983; 17:543-4. https://pubmed.ncbi.nlm.nih.gov/6135593

23. Carter BL. Labetalol (Trandate, Glaxo Inc.; Normodyne, Schering Corp.). Drug Intell Clin Pharm. 1983; 17:704-12. https://pubmed.ncbi.nlm.nih.gov/6354658

24. Gross F. The place of α-adrenoceptor and β-adrenoceptor blockade in the treatment of hypertension. Br J Clin Pharmacol. 1982; 13(Suppl 1):5-11S. https://pubmed.ncbi.nlm.nih.gov/7039647

25. Semplicini A, Pessina AC, Rossi GP et al. Alpha-adrenoceptor blockade by labetalol during long-term dosing. Clin Pharmacol Ther. 1983; 33:279-82.

26. Brittain RT, Drew GM, Levy GP. The α- and β-adrenoceptor potencies of labetalol and its individual stereoisomers. Br J Pharmacol. 1981; 73:282-3P.

27. Bellamy GR, Hunyor SN, Roffe D et al. Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment. Br J Clin Pharmacol. 1983; 16:9-16. https://pubmed.ncbi.nlm.nih.gov/6882628

28. Farmer JB, Kennedy I, Levy GB et al. Pharmacology of AH 5158; a drug which blocks both α- and β-adrenoceptors. Br J Pharmacol. 1972; 45:660-75. https://pubmed.ncbi.nlm.nih.gov/4404413

29. Weber MA, Drayer JIM. Central and peripheral blockade of the sympathetic nervous system. Am J Med. 1984; 77(Suppl 4A):110-8. https://pubmed.ncbi.nlm.nih.gov/6148889

30. Baum T, Sybertz EJ. Pharmacology of labetalol in experimental animals. Am J Med. 1983; 75(Suppl 4A):15-23. https://pubmed.ncbi.nlm.nih.gov/6314811

31. Yuen PC, Taddei CR, Wyka BE et al. Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm. 1983; 40:1007-9. https://pubmed.ncbi.nlm.nih.gov/6869384

32. Richards DA, Prichard BNC. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979; 8(Suppl 2):89-93S. https://pubmed.ncbi.nlm.nih.gov/552303

33. McNeil JJ, Anderson AE, Louis WJ. Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol. 1979; 8(Suppl 2):157-61S.

34. Leitz F, Bariletto S, Chung M et al. Bioavailability/pharmacokinetics of labetalol in normotensive male volunteers. Fed Proc. 1982; 41:1557.

35. Kanto J, Allonen H, Kleimola T et al. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1981; 19:41-4. https://pubmed.ncbi.nlm.nih.gov/7203731

36. Mantyla R, Allonen H, Kanto J et al. Effect of food on the bioavailability of labetalol. Br J Clin Pharmacol. 1980; 9:435-7. https://pubmed.ncbi.nlm.nih.gov/7378263

37. Daneshmend TK, Roberts CJC. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol. 1982; 14:73-8. https://pubmed.ncbi.nlm.nih.gov/7104169

38. Kelly JG, McGarry K, O’Malley K et al. Bioavailability of labetalol increases with age. Br J Clin Pharmacol. 1982; 14:304-5. https://pubmed.ncbi.nlm.nih.gov/7104187

39. Homeida M, Jackson L, Roberts CJC. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978; 2:1048-50. https://pubmed.ncbi.nlm.nih.gov/709214

40. Daneshmend TK, Homeida M, Roberts CJC. The effect of hepatosplenic schistosomiasis on the pharmacokinetics of metronidazole and labetalol. Br J Clin Pharmacol. 1982; 14:152-3P.

41. McNeil JJ, Anderson AE, Louis WJ et al. Labetalol steady-state pharmacokinetics in hypertensive patients. Br J Clin Pharmacol. 1982; 13(Suppl 1):75-80S.

42. Sanders GL, Routledge PA, Ward A et al. Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy. Br J Clin Pharmacol. 1979; 8(Suppl 2):153-5S.

43. Maronde RF, Robinson D, Vlachakis ND et al. Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of antihypertensive effects of labetalol. Am J Med. 1983; 75(Suppl 4A):40-6. https://pubmed.ncbi.nlm.nih.gov/6356898

44. Brittain RT, Drew GM, Levy GP. The α- and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol. 1982; 77:105-14. https://pubmed.ncbi.nlm.nih.gov/6127131

45. Alam AS. Identification of labetalol precipitate. Am J Hosp Pharm. 1984; 41:74. https://pubmed.ncbi.nlm.nih.gov/6695936

46. McNeil JJ, Anderson AE, Louis WJ. An analysis of the blood pressure response to labetalol in hypertensive patients. Clin Sci. 1981; 61(Suppl):449-52S.

47. Lund-Johansen P. Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension. Am J Med. 1983; 75(Suppl 4A):24-31. https://pubmed.ncbi.nlm.nih.gov/6638038

48. Serlin MJ, Orme MC, Maciver M et al. Rate of onset of hypotensive effect of oral labetalol. Br J Clin Pharmacol. 1979; 7:165-8. https://pubmed.ncbi.nlm.nih.gov/760748

49. Lund-Johansen P, Bakke OM. Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension. Br J Clin Pharmacol. 1979; 7:169-74. https://pubmed.ncbi.nlm.nih.gov/760749

50. Richards DA, Maconochie JG, Bland RE et al. Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol. 1977; 11:85-90. https://pubmed.ncbi.nlm.nih.gov/14010

51. Cumming AMM, Brown JJ, Lever AF et al. Intravenous labetalol in the treatment of severe hypertension. Br J Clin Pharmacol. 1982; 13(Suppl 1):93-6S.

52. Dal Palu C, Pessina AC, Semplicini A et al. Intravenous labetalol in severe hypertension. Br J Clin Pharmacol. 1982; 13(Suppl 1):97-9S.

53. Cressman MD, Vidt DG, Gifford RW et al. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. Am Heart J. 1984; 107(5 Part 1):980-5. https://pubmed.ncbi.nlm.nih.gov/6720529

54. Trust PM, Rosei EA, Brown JJ et al. Effect of blood pressure, angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol. Br J Clin Pharmacol. 1976; 3(Suppl 3):799-803. https://pubmed.ncbi.nlm.nih.gov/791333

55. Rosei EA, Trust PM, Brown JJ et al. Effects of intravenous labetalol on blood pressure, angiotensin II and aldosterone in hypertension: comparison with propranolol. Clin Sci Mol Med. 1976; 51(Suppl 3):497-9S.

56. Davies AB, Bala Subramanian V, Gould B et al. Rapid reduction of blood pressure with acute oral labetalol. Br J Clin Pharmacol. 1982; 13:705-10. https://pubmed.ncbi.nlm.nih.gov/7082539

57. Rossi A, Ziacchi V, Lomanto B. The hypotensive effect of a single daily dose of labetalol: a preliminary study. Int J Clin Pharmacol Ther Toxicol. 1982; 20:438-45. https://pubmed.ncbi.nlm.nih.gov/6754634

58. Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976; 3(Suppl 3):695-710. https://pubmed.ncbi.nlm.nih.gov/990152

59. Chung M, Ning J, Radwanski E et al. Multiple-dose pharmacokinetics of labetalol in hypertensive patients. In: Abstracts of papers presented before the APhA Academy of Pharmaceutical Sciences. Washington, DC: American Pharmaceutical Association; 1982; 12(1):49. Abstract.

60. Wood AJ, Ferry DG, Bailey RR. Elimination kinetics of labetalol in severe renal failure. Br J Clin Pharmacol. 1982; 13(Suppl 1):81-6S. https://pubmed.ncbi.nlm.nih.gov/7066158

61. Baum T, Watkins RW, Sybertz EJ et al. Antihypertensive and hemodynamic actions of SCH 19927, the R, R-isomer and labetalol. J Pharmacol Exp Ther. 1981; 218:444-52. https://pubmed.ncbi.nlm.nih.gov/7252843

62. Sybertz EJ, Sabin CS, Pula KK et al. Alpha and beta adrenoceptor blocking properties of labetalol and its R, R-isomer, SCH 19927. J Pharmacol Exp Ther. 1981; 218:435-43. https://pubmed.ncbi.nlm.nih.gov/6114171

63. Rubin PC, Butters L, Kelman AW et al. Labetalol disposition and concentration-effect relationships during pregnancy. Br J Clin Pharmacol. 1983; 15:465-70. https://pubmed.ncbi.nlm.nih.gov/6849783

64. Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol. 1979; 8(Suppl 2):211-5S.

65. Riley AJ. Clinical pharmacology of labetalol in pregnancy. J Cardiovasc Pharmacol. 1982; 3(Suppl 1):S53-9.

66. Nylund L, Lunell NO, Lewander R et al. Labetalol for the treatment of hypertension in pregnancy: pharmacokinetics and effects on the uteroplacental blood flow. Acta Obstet Gynecol Scand. 1984; 118(Suppl):71-3.

67. Poynter D, Martin LE, Harrison C et al. Affinity of labetalol for ocular melanin. Br J Clin Pharmacol. 1976; 3(Suppl 3):711-20. https://pubmed.ncbi.nlm.nih.gov/990153

68. Michael CA. The evaluation of labetalol in the treatment of hypertension complicating pregnancy. Br J Clin Pharmacol. 1982; 13(Suppl 1):127-31S. https://pubmed.ncbi.nlm.nih.gov/7066151

69. Leitz F, Bariletto S, Gural R et al. Secretion of labetalol in breast milk in lactating women. Fed Proc. 1983; 42:378.

70. Lardoux H, Gerard J, Blazquez G et al. Which beta-blocker in pregnancy-induced hypertension? Lancet. 1983; 2:1194. Letter. (IDIS 178452)

71. Walstad AA, Berg KJ, Wessel-Aas T et al. Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand. 1982; 212(Suppl):135-41.

72. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. https://pubmed.ncbi.nlm.nih.gov/6150424

73. Anon. Drugs for hypertensive emergencies. Med Lett Drugs Ther. 1985; 27:22-4. https://pubmed.ncbi.nlm.nih.gov/3883117

74. Davidov ME, Moir GD, Poland MP et al. Monotherapy in the treatment of mild hypertension: a double-blind study. Am J Med. 1983; 75(Suppl 4A): 47-53.

75. Frishman WH, Michelson EL, Johnson BF et al. Multiclinic comparison of labetalol and metoprolol in treatment of mild to moderate systemic hypertension. Am J Med. 1983; 75(Suppl 4A):54-67. https://pubmed.ncbi.nlm.nih.gov/6356900

76. Michelson EL, Frishman WH, Lewis JE et al. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med. 1983; 75(Suppl 4A):68-80. https://pubmed.ncbi.nlm.nih.gov/6356901

77. Bloomfield SS, Lucas CP, Gantt CL et al. Step II treatment with labetalol for essential hypertension. Am J Med. 1983; 75(Suppl 4A):81-6. https://pubmed.ncbi.nlm.nih.gov/6356902

78. Wallin JD, Wilson D, Winer N et al. Treatment of severe hypertension with labetalol compared with methyldopa and furosemide. Am J Med. 1983; 75(Suppl 4A):87-94. https://pubmed.ncbi.nlm.nih.gov/6356903

79. Wilson DJ, Wallin JD, Vlachakis ND et al. Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983; 75(Suppl 4A):95-102. https://pubmed.ncbi.nlm.nih.gov/6139020

80. McAreavey D, Ramsey LE, Latham L et al. “Third drug” trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. BMJ. 1984; 288:106-11. https://pubmed.ncbi.nlm.nih.gov/6419809

81. Waal-Manning HJ, Simpson FO. Review of long-term treatment with labetalol. Br J Clin Pharmacol. 1982; 13(Suppl 1):66-73S.

82. Kane JA. Labetalol in general practice: a review. Br J Clin Pharmacol. 1982; 13(Suppl 1):59-63S.

83. Breckenridge A, Orme M, Serlin MJ et al. Labetalol in essential hypertension. Br J Clin Pharmacol. 1982; 13(Suppl 1):37-39S.

84. Mancia G, Pomidossi G, Parati G et al. Blood pressure response to labetalol in twice and three times daily administration during a 24-hour period. Br J Clin Pharmacol. 1982; 13(Suppl 1):27-35S.

85. Takeda T, Kaneko Y, Omae T et al. The use of labetalol in Japan: results of multicentre clinical trials. Br J Clin Pharmacol. 1982; 13(Suppl 1):49-57S.

86. Sanders GL, Davies DM, Gales GM et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):149-51S. https://pubmed.ncbi.nlm.nih.gov/385023

87. NcNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):163-6S. https://pubmed.ncbi.nlm.nih.gov/486291

88. Kane J, Gregg I. A long-term study of labetalol in general practice. Br J Clin Pharmacol. 1979; 8(Suppl 2):167-70S.

89. Prichard BNC, Boakes HJ, Hernandez R. Long-term treatment of hypertension with labetalol. Br J Clin Pharmacol. 1979; 8(Suppl 2):171-7S.

90. New Zealand Hypertension Study Group. A multicentre open trial of labetalol in New Zealand. Br J Clin Pharmacol. 1979; 8(Suppl 2):179-82S. https://pubmed.ncbi.nlm.nih.gov/486293

91. Williams LC, Murphy MJ, Parsons V. Labetalol in severe and resistant hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):143-7S. https://pubmed.ncbi.nlm.nih.gov/39585

92. Ghose RR. Acute management of severe hypertension with oral labetalol. Br J Clin Pharmacol. 1979; 8(Suppl 2):189-93S. https://pubmed.ncbi.nlm.nih.gov/385027

93. Cumming AMM, Brown JJ, Lever AF et al. Treatment of severe hypertension by repeated bolus injections of labetalol. Br J Clin Pharmacol. 1979; 8(Suppl 2):199-204S.

94. Smith WB, Clifton GG, O’Neill WM et al. Antihypertensive effectiveness of intravenous labetalol in accelerated hypertension. Hypertension. 1983; 5:579-83. https://pubmed.ncbi.nlm.nih.gov/6862581

95. Lamming GD, Symonds EM. Use of labetalol and methyldopa in pregnancy-induced hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):217-22S.

96. Prichard BNC, Richards DA. Comparison of labetalol with other anti-hypertensive drugs. Br J Clin Pharmacol. 1982; 13(Suppl 1):41-7S.

97. Seedat YK. The stepped-care approach to the treatment of hypertension in black patients. S Afr Med J. 1982; 62:1033-5. https://pubmed.ncbi.nlm.nih.gov/6817425

98. Thompson FD, Joekes AM, Hussein MM. Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br J Clin Pharmacol. 1979; 8(Suppl 2):129-33S.

99. van der Veur E, ten Berge BS, Donker AJ et al. Comparison of labetalol, propranolol and hydralazine in hypertensive out-patients. Eur J Clin Pharmacol. 1982; 21:457-60. https://pubmed.ncbi.nlm.nih.gov/7042373

100. Weber MA, Drayer JIM, Kaufman CA. The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences. J Clin Pharmacol. 1984; 24:103-2. https://pubmed.ncbi.nlm.nih.gov/6143765

101. Cubeddu LX, Carr ME, Fuenmayor NJ. Beta blockade by oral propranolol and labetalol. Clin Pharmacol Ther. 1985; 37:277-83. https://pubmed.ncbi.nlm.nih.gov/2857602

102. Koch G. Combined α- and β-adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Br J Clin Pharmacol. 1976; 3(Suppl 3):729-32. https://pubmed.ncbi.nlm.nih.gov/10951

103. Lijnen PJ, Amery AK, Fagard RH et al. Effects of labetalol on plasma renin, aldosterone, and catecholamines in hypertensive patients. J Cardiovasc Pharmacol. 1979; 1:625-32. https://pubmed.ncbi.nlm.nih.gov/94628

104. Weidmann P, de Chatel R, Zeigler WH et al. Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Am J Cardiol. 1978; 41:570-6. https://pubmed.ncbi.nlm.nih.gov/343564

105. Salvetti A, Pedrinelli R, Sassano P et al. Effect of increasing doses of labetalol on blood pressure, plasma renin activity and aldosterone in hypertensive patients. Clin Sci. 1979; 57:401-4S. https://pubmed.ncbi.nlm.nih.gov/519947

106. Dawson A, Johnson BF, Smith IK. Comparison of the effects of labetalol, bendrofluazide and their combination in hypertension. Br J Clin Pharmacol. 1979; 8:149-54. https://pubmed.ncbi.nlm.nih.gov/385023

107. Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Am Heart J. 1979; 98:660-5. https://pubmed.ncbi.nlm.nih.gov/386753

108. Brogden RN, Heel RC, Speight TM et al. Labetalol: a review of its pharmacology and therapeutic uses in hypertension. Drugs. 1978; 15:251-70. https://pubmed.ncbi.nlm.nih.gov/25757

109. Tcherdakoff P. Side effects with long term labetalol: open study of 251 patients in a single center. Pharmatherapeutica. 1983; 3:342-8. https://pubmed.ncbi.nlm.nih.gov/6844370

110. Michelson EL, Frishman WH, Sawin HS et al. Long-term efficacy and safety of labetalol in the treatment of hypertension. J Am Coll Cardiol. 1983; 1:611.

111. Harley A, Coverdale HA. The electrophysiological effects of intravenous labetalol in man. Eur J Clin Pharmacol. 1981; 20:241-4. https://pubmed.ncbi.nlm.nih.gov/7308279

112. Mehta J, Cohn JN. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation. 1977; 55:370-5. https://pubmed.ncbi.nlm.nih.gov/12880

113. Koch G. Cardiovascular dynamics after acute and long-term α- and β-adrenoceptor blockade at rest, supine and standing, and during exercise. Br J Clin Pharmacol. 1979; 8(Suppl 2):101-5S.

114. Svendsen TL, Rasmussen S, Hartling OJ. Sequential haemodynamic effects of labetalol at rest and during exercise in essential hypertension. Postgrad Med J. 1980; 56(Suppl 2):21-6. https://pubmed.ncbi.nlm.nih.gov/7433338

115. Joekes AM, Thompson FD. Acute hemodynamic effects of labetalol and its subsequent use as an oral hypotensive agent. Br J Clin Pharmacol. 1976; 3(Suppl 3):789-93. https://pubmed.ncbi.nlm.nih.gov/990156

116. Prichard BNC, Thompson FO, Boakes AJ et al. Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydralazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin Sci Mol Med. 1975; 48:97-100S. https://pubmed.ncbi.nlm.nih.gov/1167821

117. Bahlmann J, Brod J, Hubrich W et al. Effect of and α-and β-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):113-7S.

118. Trap-Jensen J, Clausen JP, Hartling OJ et al. Immediate effects of labetalol on central, splanchnic-hepatic, and forearm haemodynamics during pleasant emotional stress in hypertensive patients. Postgrad Med J. 1980; 56(Suppl 2):37-42. https://pubmed.ncbi.nlm.nih.gov/7433341

119. Agabiti-Rosei E, Alicandri CL, Beschi M et al. The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels. Br J Clin Pharmacol. 1982; 13(Suppl 1):87-92S. https://pubmed.ncbi.nlm.nih.gov/7039649

120. Dunn FG, Oigman W, Messerli FH et al. Hemodynamic effects of intravenous labetalol in essential hypertension. Clin Pharmacol Ther. 1983; 33:139-43. https://pubmed.ncbi.nlm.nih.gov/6822026

121. Edwards RC, Raftery EB. Haemodynamic effects of long-term oral labetalol. Br J Clin Pharmacol. 1976; 3(Suppl 3):733-6. https://pubmed.ncbi.nlm.nih.gov/791328

122. Fagard R, Amery A, Reybrouck T et al. Response of the systemic and pulmonary circulation to alpha- and beta-receptor blockade (labetalol) at rest and during exercise in hypertensive patients. Circulation. 1979; 69:1214-9.

123. Lund-Johansen P. Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br J Clin Pharmacol. 1979; 8(Suppl 2):107-11S.

124. Griffith DNW, James IM, Newbury PA et al. The effect of β-adrenergic receptor blocking drugs on cerebral blood flow. Br J Clin Pharmacol. 1979; 7:491-4. https://pubmed.ncbi.nlm.nih.gov/38822

125. Taylor SH, Silke B, Nelson GIC et al. Haemodynamic advantages of combined alpha-blockade and beta-blockade over beta-blockade alone in patients with coronary heart disease. BMJ. 1982; 285:325-7. https://pubmed.ncbi.nlm.nih.gov/6807469

126. Gagnon RM, Morissette M, Presant S et al. Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease. Am J Cardiol. 1982; 49:1267-9. https://pubmed.ncbi.nlm.nih.gov/7064851

127. Condorelli M, Brevetti G, Chiarello M et al. Effects of combined α- and β-blockade by labetalol in patients with coronary artery disease. Br J Clin Pharmacol. 1982; 13(Suppl 1):101-10S.

128. Richards DA. Pharmacological effects of labetalol in man. Br J Clin Pharmacol. 1976; 3(Suppl 3):721-3. https://pubmed.ncbi.nlm.nih.gov/10949

129. Louis WJ, Christophidis N, Brignell M et al. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust N Z J Med. 1978; 8:602-9. https://pubmed.ncbi.nlm.nih.gov/285681

130. Larochelle P, Hamet P, Hoffman B et al. Labetalol in essential hypertension. J Cardiovasc Pharmacol. 1980; 2:751-9. https://pubmed.ncbi.nlm.nih.gov/6160325

131. Kornerup HJ, Pedersen EB, Christensen NJ et al. Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension. Eur J Clin Pharmacol. 1979; 16:305-10. https://pubmed.ncbi.nlm.nih.gov/520398

132. Cumming AMM, Brown JJ, Fraser R et al. Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol. 1979; 8:359-64. https://pubmed.ncbi.nlm.nih.gov/508511

133. Barbieri C, Ferrari C, Caldara R et al. Endocrine and metabolic effects of labetalol in man. J Cardiovasc Pharmacol. 1981; 3:986-91. https://pubmed.ncbi.nlm.nih.gov/6168866

134. Riley AJ. Some further evidence for partial agonist activity of labetalol. Br J Clin Pharmacol. 1980; 9:517-8. https://pubmed.ncbi.nlm.nih.gov/6104978

135. Andersson O, Berglund G, Hansson L. Antihypertensive action, time of onset and effects on carbohydrate metabolism of labetalol. Br J Clin Pharmacol. 1976; 3(Suppl 3):757-61. https://pubmed.ncbi.nlm.nih.gov/1032990

136. Sommers DEK, DeVilliers LS, Van Wyk M et al. The effects of labetalol and oxprenolol on blood lipids. S Afr Med J. 1981; 60:379-80. https://pubmed.ncbi.nlm.nih.gov/7025257

137. Pagnan A, Pessina AC, Zanetti G et al. Effects of labetalol on lipid and carbohydrate metabolism. Pharmacol Res Commun. 1979; 11:227-36. https://pubmed.ncbi.nlm.nih.gov/223175

138. McGonigle RJS, Williams L, Murphy MJ. Labetalol and lipids. Lancet. 1981; 1:163. https://pubmed.ncbi.nlm.nih.gov/6109848

139. Frishman W, Michelson E, Johnson B et al. Effects of beta-adrenergic blockade on plasma lipids: a double-blind randomized placebo-controlled multi-center comparison of labetalol and metoprolol in patients with hypertension. Am J Cardiol. 1982; 49:284.

140. Barbieri C, Larovere MT, Mariotti G et al. Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol. 1982; 16:615-9.

141. Rasmussen S, Nielsen PE. Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol. 1981; 12:349-53. https://pubmed.ncbi.nlm.nih.gov/7295465

142. Pedersen EB, Larsen JS. Effect of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension. Postgrad Med J. 1980; 56(Suppl 2):27-32. https://pubmed.ncbi.nlm.nih.gov/7433339

143. Cruz F, O’Neill WM, Clifton G et al. Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther. 1981; 30:57-63. https://pubmed.ncbi.nlm.nih.gov/7237899

144. Valvo E, Previato G, Tessitore N et al. Effects of the long-term administration of labetalol on blood pressure, hemodynamics and renal function in essential and renal hypertension. Curr Ther Res. 1981; 29:634-43.

145. Malini PL, Strocchi E, Negroni S et al. Renal haemodynamics after chronic treatment with labetalol and propranolol. Br J Clin Pharmacol. 1982; 13(Suppl 1):123-6S.

146. Bailey RR. Labetalol in the treatment of patients with hypertension and renal function impairment. Br J Clin Pharmacol. 1979; 8(Suppl 2):134-40S.

147. Williams JG, DeVoss K, Croswell PW. Labetalol in the treatment of hypertensive renal patients. Med J Aust. 1978; 1:225-8. https://pubmed.ncbi.nlm.nih.gov/26015

148. Hunyor SN, Bauer GE, Ross M et al. Labetalol and propranolol in mild hypertensives: comparison of blood pressure and plasma volume effects. Aust N Z J Med. 1980; 10:162-6. https://pubmed.ncbi.nlm.nih.gov/6930206

149. Adam WR, Meagher EJ, Barter CE. Labetalol, beta-blockers and acute deterioration of chronic airway obstruction. Clin Exp Hypertens. 1982; 4:1419-28.

150. Richards DA, Woodings EP, Maconochie JG. Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise. Br J Clin Pharmacol. 1977; 4:15-21. https://pubmed.ncbi.nlm.nih.gov/843418

151. Maconochie JG, Woodings EP, Richards DA. Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol. 1977; 4:157-62. https://pubmed.ncbi.nlm.nih.gov/861131

152. Pearson RM, Havard CWH. Intravenous labetalol in hypertensive patients treated with β-adrenoceptor blocking drugs. Br J Clin Pharmacol. 1976; 3(Suppl 3):795-8. https://pubmed.ncbi.nlm.nih.gov/10953

153. Breckenridge AM, Macnee CM, Orme ML et al. Rate of onset of hypotensive response with oral labetalol. Br J Clin Pharmacol. 1977; 4:388P. https://pubmed.ncbi.nlm.nih.gov/901712

154. Skinner C, Gaddie J, Palmer KNV. Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma. Br Med J. 1975; 2:59-61. https://pubmed.ncbi.nlm.nih.gov/236806

155. Mazzola C, Guffanti E, Vacarella A et al. Respiratory effects of labetalol in anginous or hypertensive patients. Curr Ther Res. 1982; 31:219-31.

156. George RB, Manocha K, Burford JG et al. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest. 1983; 83:457-60. https://pubmed.ncbi.nlm.nih.gov/6337786

157. Anavekar SN, Barter C, Adam WR et al. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. J Cardiovasc Pharmacol. 1982; 4:374-7.

158. Nicholls DP, Husaini MH, Bulpitt CJ et al. Comparison of labetalol and propranolol in hypertension. Br J Clin Pharmacol. 1980; 9:233-7. https://pubmed.ncbi.nlm.nih.gov/6988003

159. Gomez G, Phillips LA. Labetalol (″Trandate’) in hypertension: a multicentre study in general practice. Curr Med Res Opin. 1980; 6:677-84. https://pubmed.ncbi.nlm.nih.gov/7428406

160. Lubbe WF, White DA. Labetalol in hypertensive patients with angina pectoris: beneficial effect of combined α- and β-blockade. Clin Sci Mol Med. 1978; 55:283-6S.

161. Besterman EMM, Spencer M. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br J Clin Pharmacol. 1979; 8(Suppl 2):205-9S. https://pubmed.ncbi.nlm.nih.gov/497086

162. Halprin S, Frishman W, Kirschner M et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part II. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience. Am Heart J. 1980; 99:388-96. https://pubmed.ncbi.nlm.nih.gov/7355700

163. Opie LH, White D, Lee J. Alternatives to β-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol. Br J Clin Pharmacol. 1982; 13(Suppl 1):115-22S.

164. Frishman WH, Strom JA, Kirschner M et al. Labetalol therapy in patients with systemic hypertension and angina pectoris: effects of combined alpha and beta adrenoceptor blockade. Am J Cardiol. 1981; 48:917-28. https://pubmed.ncbi.nlm.nih.gov/6118060

165. Marx PG, Reid DS. Labetalol infusion in acute myocardial infarction with systemic hypertension. Br J Clin Pharmacol. 1979; 8(Suppl 2):233-8S. https://pubmed.ncbi.nlm.nih.gov/497089

166. Timmis AD, Fowler MB, Jaggarao NSV et al. Role of labetalol in acute myocardial infarction. Br J Clin Pharmacol. 1982; 13(Suppl 1):111-4S.

167. Timmis AD, Fowler MB, Jaggarao NSV et al. Labetalol infusion for the treatment of hypertension in acute myocardial infarction. Eur Heart J. 1980; 1:413-6. https://pubmed.ncbi.nlm.nih.gov/7274255

168. Hua ASP, Thomas GW, Kincaid-Smith P. Scalp tingling in patients on labetalol. Lancet. 1977; 2:295. https://pubmed.ncbi.nlm.nih.gov/69898

169. Bailey RR. Scalp tingling and difficulty in micturition in patients on labetalol. Lancet. 1977; 2:720. https://pubmed.ncbi.nlm.nih.gov/71532

170. Gabriel R. Circumoral paraesthesiae and labetalol. Br Med J. 1978; 1:580. https://pubmed.ncbi.nlm.nih.gov/630239

171. Kristensen BO. Labetalol-induced Peyronie’s disease. A case report. Acta Med Scand. 1979; 206:511-2. https://pubmed.ncbi.nlm.nih.gov/231377

172. Law MR, Copland RFP, Armistead JG et al. Labetalol and priapism. Br Med J. 1980; 1:115.

173. Teicher A, Rosenthal T, Kissin E et al. Labetalol-induced toxic myopathy. BMJ. 1981; 282:1824-5. https://pubmed.ncbi.nlm.nih.gov/6786636

174. Frais MA, Bayley TJ. Left ventricular failure with labetalol. Postgrad Med J. 1979; 55:567-8. https://pubmed.ncbi.nlm.nih.gov/514938

175. Griffiths ID, Richardson J. Lupus-type illness associated with labetalol. Br Med J. 1979; 2:496-7. https://pubmed.ncbi.nlm.nih.gov/314829

176. Booth RJ, Wilson JD, Bullock JY. β-Adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther. 1982; 31:555-63. https://pubmed.ncbi.nlm.nih.gov/6122525

177. Wilson JD, Booth RJ, Bullock JY et al. Anti-mitochondrial antibodies associated with labetalol. Lancet. 1980; 2:312-3. https://pubmed.ncbi.nlm.nih.gov/6105456

178. Richards DA, Prichard BNC, Boakes AJ et al. Pharmacological basis for antihypertensive effects of intravenous labetalol. Br Heart J. 1977; 39:99-106. https://pubmed.ncbi.nlm.nih.gov/12778

179. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: The Williams & Wilkins Co; 1984:I-10.

180. Daneshmend TK, Roberts CJC. Cimetidine and bioavailability of labetalol. Lancet. 1981; 1:565. https://pubmed.ncbi.nlm.nih.gov/6111669

181. Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol. Br J Clin Pharmacol. 1976; 3(Suppl 3):809-15. https://pubmed.ncbi.nlm.nih.gov/990158

182. Bailey RR. Labetalol in the treatment of a patient with phaeochromocytoma: a case report. Br J Clin Pharmacol. 1979; 8(Suppl 2):141-2S.

183. Kaufman L. Use of labetalol during hypotensive anaesthesia and in the management of phaeochromocytoma. Br J Clin Pharmacol. 1979; 8(Suppl 2):229-32S. https://pubmed.ncbi.nlm.nih.gov/497088

184. Reach G, Thibonnier M, Chevillard C et al. Effect of labetalol on blood pressure and plasma catecholamine concentrations in patients with phaeochromocytoma. Br Med J. 1980; 1:1300-1.

185. Lubbe WF. Hypertension in pregnancy: pathophysiology and management. Drugs. 1984; 28:170-88. https://pubmed.ncbi.nlm.nih.gov/6147240

186. Briggs RSJ, Birtwell AJ, Pohl JEF. Hypertensive response to labetalol in phaeochromocytoma. Lancet. 1978; 1:1045-6.

187. Feek CM, Earnshaw PM. Hypertensive response to labetalol in phaeochromocytoma. Br Med J. 1980; 2:387.

188. Rosenthal T, Rabinowitz B, Boichis H et al. Use of labetalol in hypertensive patients during discontinuation of clonidine therapy. Eur J Clin Pharmacol. 1981; 20:237-40. https://pubmed.ncbi.nlm.nih.gov/6273179

189. Hurley DM, Vandogen R, Beilin LJ. Failure of labetalol to prevent hypertension due to clonidine withdrawal. Br Med J. 1979; 1:1122-3. https://pubmed.ncbi.nlm.nih.gov/444961

190. Scott DB, Buckley FP, Drummond GB et al. Cardiovascular effects of labetalol during halothane anaesthesia. Br J Clin Pharmacol. 1976; 3(Suppl 3):817-21. https://pubmed.ncbi.nlm.nih.gov/990159

191. Scott DB. The use of labetalol in anaesthesia. Br J Clin Pharmacol. 1982; 13(Suppl 1):133-5S. https://pubmed.ncbi.nlm.nih.gov/6121571

192. Cope DHP. Use of labetalol during halothane anaesthesia. Br J Clin Pharmacol. 1979; 8(Suppl 2):223-7S.

193. Cope DHP, Crawford MC. Labetalol in controlled hypotension. Administration of labetalol when adequate hypotension is difficult to achieve. Br J Anaesth. 1979; 51:359-65. https://pubmed.ncbi.nlm.nih.gov/465259

194. Jones SEF. Coarctation in children. Controlled hypotension using labetalol and halothane. Anaesthesia. 1979; 34:1052-5. https://pubmed.ncbi.nlm.nih.gov/539643

195. Kanto J, Pakkanen A, Allonen H et al. The use of labetalol as a moderate hypotensive agent in otological operations—plasma concentrations after intravenous administration. Int J Clin Pharmacol Ther Toxicol. 1980; 18:191-4. https://pubmed.ncbi.nlm.nih.gov/7390669

196. Domenighetti GM, Savary G, Stricker H. Hyperadrenergic syndrome in severe tetanus: extreme rise in catecholamines responsive to labetalol. BMJ. 1984; 288:1483-4. https://pubmed.ncbi.nlm.nih.gov/6426611

197. Cumming AMM, Brown JJ, Fraser R et al. Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol. 1979; 8:359-64. https://pubmed.ncbi.nlm.nih.gov/508511

198. Pearson RM, Havard CWH. Intravenous labetalol in hypertensive patients given by fast and slow injection. Br J Clin Pharmacol. 1978; 5:401-5. https://pubmed.ncbi.nlm.nih.gov/350248

199. Rumboldt Z, Bagatin J, Vidovic A. Diazoxide vs labetalol: a crossover comparison of short-term effects in hypertension. Int J Clin Pharm Res. 1983; 3:47-54.

200. Dundee JW, Morrow WFK. Labetalol in severe tetanus. Br Med J. 1979; 1:1121-2. https://pubmed.ncbi.nlm.nih.gov/444960

201. Hanna W, Grell GAC. Oral labetalol in the management of the sympathetic overactivity of severe tetanus. South Med J. 1980; 73:653-4. https://pubmed.ncbi.nlm.nih.gov/6103586

202. Wesley AG, Hariparasad D, Pataher M et al. Labetalol in tetanus: the treatment of sympathetic nervous system overactivity. Anaesthesia. 1983; 38:243-9. https://pubmed.ncbi.nlm.nih.gov/6837902

203. Reviewers’ comments (personal observations); 1985 Jul.

204. Modrak JB (Glaxo Inc, Research Triangle Park, NC): Personal communication; 1985 Jul.

205. Jennings K, Parsons V. A study of labetalol in patients of European, West Indian and West African origin. Br J Clin Pharmacol. 1976; 3(Suppl 3):773-5. https://pubmed.ncbi.nlm.nih.gov/990155

206. Seedat YK. Labetalol hydrochloride in the treatment of black and Indian hypertensive patients. Med Proc. 1979; 25:53-7.

207. Olivier LR, Retief JH, Buchel EH et al. Evaluation of labetalol hydrochloride in hospital outpatients. Clin Trials J. 1980; 17:75-80.

208. Flamenbaum W, Weber MA, McMahon FG et al. Monotherapy with labetalol compared with propranolol: differential effects by race. J Clin Hypertens. 1985; 1:56-69. https://pubmed.ncbi.nlm.nih.gov/3915317

209. Jackson SHD, Beevers DG, Owen L et al. Labetalol: a comparison of intravenous infusions and injections. J Pharmacother. 1980; 3:131-3.

210. Lebel M, Langlois S, Belleau LJ et al. Labetalol infusion in hypertensive emergencies. Clin Pharmacol Ther. 1985; 37:615-8. https://pubmed.ncbi.nlm.nih.gov/3891186

211. Koda-Kimble MA, Rotblatt MD. Diabetes mellitus. In: Katcher BS, Young LY, Koda-Kimble MA, eds. Applied therapeutics: the clinical use of drugs. 3rd ed. San Francisco: Applied Therapeutics, Inc; 1983:1335-414.

212. Hansten PD. Drug interactions. 4th ed. Philadelphia: Lea & Febiger; 1979:14,93-109.

213. Meretoja OA, Allonen H, Arola M et al. Combined alpha- and beta-blockade with labetalol in post-open heart surgery hypertension: reversal of hemodynamic deterioration with glucagon. Chest. 1980; 78:810-5. https://pubmed.ncbi.nlm.nih.gov/7004797

214. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.

215. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31. https://pubmed.ncbi.nlm.nih.gov/6150667

216. Hamilton CA, Jones DH, Dargie HJ et al. Does labetalol increase excretion of urinary catecholamines? Br Med J. 1978; 277:800. (IDIS 87272)

217. Miano L, Kolloch R, de Quattro V. Increased catecholamine excretion after labetalol therapy: a spurious effect of drug metabolites. Clin Chim Acta. 1979; 95:211-7. https://pubmed.ncbi.nlm.nih.gov/527220

218. Richards DA, Harris DM, Martin LE. Labetalol and urinary catecholamines. Br Med J. 1979; 278:685.

219. Romano S, Orfei S, Pozzoni L et al. Preliminary clinical trial on hypotensive and antiarrhythmic effect of labetalol. Drugs Exp Clin Res. 1981; 7:65-8.

220. Mazzola C, Ferrario N, Calzavara MP et al. Acute antihypertensive and antiarrhythmic effects of labetalol. Curr Ther Res. 1981; 29:613-33.

221. Carey B, Whalley ET. Labetalol possesses β-adrenoceptor agonist action on the rat isolated uterus. J Pharm Pharmacol. 1979; 31:791-2. https://pubmed.ncbi.nlm.nih.gov/41918

222. Carey B, Whalley ET. β-Adrenoceptor agonist activity of labetalol on the isolated rat uterus. Br J Pharmacol. 1979; 67:13-5. https://pubmed.ncbi.nlm.nih.gov/40642

223. Iezzoni DG (Schering Corporation, Kenilworth, NJ): Personal communication; 1985 Jul.

224. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol. 1981; 33:172-3. https://pubmed.ncbi.nlm.nih.gov/6116760

225. Dage RC, Hsieh CP. Direct vasodilatation by labetalol in anaesthetized dogs. Br J Pharmacol. 1980; 70:287-93. https://pubmed.ncbi.nlm.nih.gov/7426837

226. Silke B, Nelson GIC, Ahuja RC et al. Comparison of haemodynamic dose-response effects of beta- and alpha-blockade in acute myocardial infarction. Int J Cardiol. 1984; 5:317-25. https://pubmed.ncbi.nlm.nih.gov/6706437

227. George RB, Light RW, Hudson L et al. The use of labetalol for the treatment of hypertension in patients with reversible airway obstruction. J Clin Hypertens. 1985; 1:80-3. https://pubmed.ncbi.nlm.nih.gov/3836298

228. Gribbin HR, Mackay AD, Baldwin CJ et al. Bronchial and cardiac β-adrenoceptor blockade: a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol. 1981; 12:61-5. https://pubmed.ncbi.nlm.nih.gov/6264936

229. Daneshmend TK, Roberts CJC. The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. Br J Clin Pharmacol. 1984; 18:393-400. https://pubmed.ncbi.nlm.nih.gov/6487478

230. Horvath JS, Caterson RJ, Collett P et al. Labetalol and bendrofluazide: comparison of their antihypertensive effects. Med J Aust. 1979; 1:626-8. https://pubmed.ncbi.nlm.nih.gov/386062

231. Labetalol/Hydrochlorothiazide Multicenter Study Group. Labetalol and hydrochlorothiazide in hypertension. Clin Pharmacol Ther. 1985; 38:24-7. https://pubmed.ncbi.nlm.nih.gov/2860990

232. Dargie HJ, Dollery CT, Daniel J. Labetalol in resistant hypertension. Br J Clin Pharmacol. 1976; 3(Suppl 3):751-5. https://pubmed.ncbi.nlm.nih.gov/990154

233. Lilja M, Jounela AJ, Karppanen H. Comparison of labetalol and clonidine in hypertension. Eur J Clin Pharmacol. 1982; 21:363-7. https://pubmed.ncbi.nlm.nih.gov/7075640

234. Whiting G, Craswell P, Boyles P et al. Minoxidil and labetalol: very effective antihypertensive combination. Med J Aust. 1980; 1:225-6. https://pubmed.ncbi.nlm.nih.gov/7374568

235. McGrath BP, Matthews PG, Walter NM et al. Emergency treatment of severe hypertension with intravenous labetalol. Med J Aust. 1978; 2:410-1. https://pubmed.ncbi.nlm.nih.gov/732728

236. Papademetriou V, Notargiacomo AV, Khatri IM et al. Treatment of severe hypertension with intravenous labetalol. Clin Pharmacol Ther. 1982; 32:431-5. https://pubmed.ncbi.nlm.nih.gov/7116758

237. Lewis M, Kallenbach J, Germond C et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983; 4:328-32. https://pubmed.ncbi.nlm.nih.gov/6617679

238. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811. https://pubmed.ncbi.nlm.nih.gov/40429

239. Walstad RA, Berg KJ, Wessel-Aas T et al. Labetalol in the treatment of hypertension in patients with normal and impaired renal function. Acta Med Scand Suppl. 1982; 665:135-41. https://pubmed.ncbi.nlm.nih.gov/6961760

240. Vlachakis ND, Maronde RF, Maloy JW et al. Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol. Clin Pharmacol Ther. 1985; 38:503-8. https://pubmed.ncbi.nlm.nih.gov/4053487

241. Halstenson CE, Opsahl JA, Pence TV et al. The disposition and dynamics of labetalol in patients on dialysis. Clin Pharmacol Ther. 1986; 40:462-8. https://pubmed.ncbi.nlm.nih.gov/3757409

242. Schering Corporation. Normodyne injection prescribing information. Kenilworth, NJ; 1986 Aug.

243. Stricker BHC, Heijermans HSF, Braat H et al. Fever induced by labetalol. JAMA. 1986; 256:619-20. https://pubmed.ncbi.nlm.nih.gov/3723760

244. Jouppila P, Kirkinen P, Koivula A et al. Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia. Br J Obstet Gynaecol. 1986; 93:543-7. https://pubmed.ncbi.nlm.nih.gov/3524664

245. Macpherson M, Pipkin FB, Rutter N. The effect of maternal labetalol on the newborn infant. Br J Obstet Gynaecol. 1986; 93:539-42. https://pubmed.ncbi.nlm.nih.gov/3730323

246. Mehta JL, Lopez LM. Rebound hypertension following abrupt cessation of clonidine and metoprolol: treatment with labetalol. Arch Intern Med. 1987; 147:389-90. https://pubmed.ncbi.nlm.nih.gov/3813760

247. Allen & Hanburys. Trandate HCT tablets prescribing information. Research Triangle Park, NC; 1991 Apr.

248. Schering Corporation. Normozide tablets prescribing information. Kenilworth, NJ; 1989 Apr.

249. Grubb BP, Sirio C, Zelis R. Intravenous labetalol in acute aortic dissection. JAMA. 1987; 258:78-9. https://pubmed.ncbi.nlm.nih.gov/3586295

250. Cumming AMM, Davies DL. Intravenous labetalol in hypertensive emergency. Lancet. 1979; 1:929-30. https://pubmed.ncbi.nlm.nih.gov/86702

251. Grubb BP, Zelis R. Intravenous labetalol in acute aortic dissection. JAMA. 1987; 258:1732-3.

252. Binder SR, Biaggi ME. Analysis of urinary catecholamines by high-performance liquid chromatography in the presence of labetalol metabolites. J Chromatogr. 1987; 385:241-7. https://pubmed.ncbi.nlm.nih.gov/3558579

253. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. https://pubmed.ncbi.nlm.nih.gov/3365073

254. Douglas DD, Yang RD, Jansen P et al. Fatal labetalol-induced hepatic injury. Am J Med. 1989; 87:235-6. https://pubmed.ncbi.nlm.nih.gov/2757062

255. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med. 1990; 113:485.

256. Hansten PD. Drug Interactions. 6th ed. Philadelphia: Lea & Febiger, 1989:35-6.

257. Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris. Am J Cardiol. 1986; 58:551-2. https://pubmed.ncbi.nlm.nih.gov/3529913

258. Murad F. Drugs used for the treatment of angina: organic nitrates, calcium-channel blockers, and β-adrenergic antagonists. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Macmillan Publishing Company; 1990:764-813.

259. Gerber JG, Nies AS. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Macmillan Publishing Company; 1990; 784-813.

260. Zipes DP. Management of cardiac arrhythmias: pharmacological, electrical, and surgical techniques. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia: WB Saunders Company; 1988:621-57.

261. Rutherford JD, Braunwald E, Cohn P. Chronic ischemic heart disease. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia: WB Saunders Company; 1988:1314-78.

262. Dahlöf B, Eggerstsen R, Hansson L. Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol. 1988; 12(Suppl 6):S104-8.

263. Mac Carthy EP. Combination therapy of hypertension with beta-adrenoreceptor blockers and the calcium channel antagonist nitrendipine. J Cardiovasc Pharmacol. 1988; 12(Suppl 4):S76-9. https://pubmed.ncbi.nlm.nih.gov/2468880

264. Dargie HJ. Beta-blockers and calcium antagonists in angina pectoris: the potential role of combination therapy. Drugs. 1988; 35(Suppl 4):44-50. https://pubmed.ncbi.nlm.nih.gov/2897903

265. Müller FB, Bolli P, Linder L et al. Calcium antagonists and the second drug for hypertensive therapy. Am J Med. 1986; 81:25-9. https://pubmed.ncbi.nlm.nih.gov/2879444

266. Brouwer RM, Follath F, Bühler FR. Review of the cardiovascular adversity of the calcium antagonist beta-blocker combination: implications for antihypertensive therapy. J Cardiovasc Pharmacol. 1985; 7(Suppl 4):S38-44.

267. Vanhaleweyk GL, Serruys PW, Hugenholtz PG. Anti-anginal, electrophysiologic and hemodynamic effects of combined beta-blocker/calcium antagonist therapy. Eur Heart J. 1983; 4(Suppl D):117-28. https://pubmed.ncbi.nlm.nih.gov/6137370

268. O’Hara MJ, Khurmi NS, Bowles MJ et al. Diltiazem and propranolol combination for the treatment of chronic stable angina pectoris. Clin Cardiol. 1987; 10:115-23. https://pubmed.ncbi.nlm.nih.gov/3545577

269. Dargie HJ, Lynch PG, Krikler DM et al. Nifedipine and propranolol: a beneficial drug interaction. Am J Med. 1981; 71:676-82. https://pubmed.ncbi.nlm.nih.gov/7025625

270. Pfisterer M, Müller-Brand J, Burkart F. Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction. Am J Cardiol. 1982; 49:1259-66. https://pubmed.ncbi.nlm.nih.gov/7064850

271. Kieval J, Kirsten EB, Kessler KM et al. The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol. Circulation. 1982; 65:653-9. https://pubmed.ncbi.nlm.nih.gov/7060243

272. Packer M, Meller J, Medina N et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation. 1982; 65:660-8. https://pubmed.ncbi.nlm.nih.gov/7060244

273. Packer M, Leon MB, Bonow RO et al. Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. Am J Cardiol. 1982; 50:903-12. https://pubmed.ncbi.nlm.nih.gov/6751066

274. Gifford RW Jr. Management of hypertensive crises. JAMA. 1991; 266:829-35. https://pubmed.ncbi.nlm.nih.gov/1865522

275. Michelson EL. Labetalol hepatotoxicity. Ann Intern Med. 1991; 114:341. https://pubmed.ncbi.nlm.nih.gov/2018583

276. Harvengt C. Labetalol hepatotoxicity. Ann Intern Med. 1991; 114:341. https://pubmed.ncbi.nlm.nih.gov/2018583

278. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. https://pubmed.ncbi.nlm.nih.gov/8422205

279. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-38. https://pubmed.ncbi.nlm.nih.gov/1969567

280. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

281. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-74. https://pubmed.ncbi.nlm.nih.gov/1969518

282. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64. https://pubmed.ncbi.nlm.nih.gov/2046107

283. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). Lancet. 1991; 338:1281-5. https://pubmed.ncbi.nlm.nih.gov/1682683

284. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-12. https://pubmed.ncbi.nlm.nih.gov/1445513

285. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol. 1990; 163:1689-1712.

286. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

287. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

288. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. https://pubmed.ncbi.nlm.nih.gov/7637142

289. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

290. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.

291. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.

292. Sidmark Laboratories. Verapamil hydrochloride tablets prescribing information. East Hanover, NJ; 1996 Apr.

293. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

294. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. https://pubmed.ncbi.nlm.nih.gov/8622249

295. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. https://pubmed.ncbi.nlm.nih.gov/9042847

298. ACOG task force on hypertension in pregnancy: hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.

299. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. https://pubmed.ncbi.nlm.nih.gov/9515998

301. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.

303. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. https://pubmed.ncbi.nlm.nih.gov/9827842

304. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. https://pubmed.ncbi.nlm.nih.gov/9831300

305. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317:703-13. https://pubmed.ncbi.nlm.nih.gov/9732337

306. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15 from American Diabetes Association web site. http://www.dtu.ox.ac.uk/ukpds

307. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. https://pubmed.ncbi.nlm.nih.gov/9732338

308. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.

310. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: apporaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.

311. Glaxo Wellcome. Trandate (labetalol hydrochloride) injection prescribing information. In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999 (Suppl A):A166.

312. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.

313. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342:905-12. https://pubmed.ncbi.nlm.nih.gov/10738048

314. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342:969-70. https://pubmed.ncbi.nlm.nih.gov/10738057

315. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. https://pubmed.ncbi.nlm.nih.gov/10818056

316. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. https://pubmed.ncbi.nlm.nih.gov/10818055

317. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. https://pubmed.ncbi.nlm.nih.gov/10977801

318. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. https://pubmed.ncbi.nlm.nih.gov/9635947

319. Pattishall EN. Dear healthcare provider letter regarding dispensing errors involving Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline; undated.

320. Pattishall EN. Dear healthcare provider letter regarding dispensing errors involving Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline; 2001 Aug.

322. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60. https://pubmed.ncbi.nlm.nih.gov/12093785

324. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. https://pubmed.ncbi.nlm.nih.gov/12479770

325. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. https://pubmed.ncbi.nlm.nih.gov/12479763

327. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

329. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

332. Carter B for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Personal communication.

333. National high blood pressure education program working group on hypertension control in children and adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. https://pubmed.ncbi.nlm.nih.gov/15286277

334. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. https://pubmed.ncbi.nlm.nih.gov/15811979

335. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. https://pubmed.ncbi.nlm.nih.gov/15811986

337. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE) a randomised trial against atenolol. Lancet. 2002;359:995-1003.

338. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 7:CD001449. https://pubmed.ncbi.nlm.nih.gov/23857334

339. ASHP. Standardize 4 Safety: pediatric continuous infusion standard. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety

340. ASHP. Standardize 4 Safety: adult continuous infusion standard. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety

342. ASHP. Standardize 4 Safety: compounded oral liquid standards. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website https://www.ashp.org/standardize4safety

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. https://pubmed.ncbi.nlm.nih.gov/24352797

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. https://pubmed.ncbi.nlm.nih.gov/23817082

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. https://pubmed.ncbi.nlm.nih.gov/24243703

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. https://pubmed.ncbi.nlm.nih.gov/24341872

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. https://pubmed.ncbi.nlm.nih.gov/24424788

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. https://pubmed.ncbi.nlm.nih.gov/24549531

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. https://pubmed.ncbi.nlm.nih.gov/24352710

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. https://pubmed.ncbi.nlm.nih.gov/24352759

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. https://pubmed.ncbi.nlm.nih.gov/24591473

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. https://pubmed.ncbi.nlm.nih.gov/24788967

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425.

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. https://pubmed.ncbi.nlm.nih.gov/24641124

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

540. Magee LA, Pels A, Helewa M et al., for the Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014; 4:105-45. https://pubmed.ncbi.nlm.nih.gov/26104418

542. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131:1949-62. https://pubmed.ncbi.nlm.nih.gov/17565029

600. Hospira, Inc. Labetalol hydrochloride injection prescribing information. Lake Forest, IL; 2018 Apr.

700. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :. http://circ.ahajournals.org/content/134/13/e282.long

701. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.

702. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34. https://pubmed.ncbi.nlm.nih.gov/10600

703. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.

704. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8. (IDIS 169422)

705. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. https://pubmed.ncbi.nlm.nih.gov/2869400

706. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. https://pubmed.ncbi.nlm.nih.gov/2881524

707. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.

708. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.

709. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. https://pubmed.ncbi.nlm.nih.gov/6114433

710. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. https://pubmed.ncbi.nlm.nih.gov/581782

711. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. https://pubmed.ncbi.nlm.nih.gov/2878346

712. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. https://pubmed.ncbi.nlm.nih.gov/2883867

1101. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 https://pubmed.ncbi.nlm.nih.gov/28827377

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. https://pubmed.ncbi.nlm.nih.gov/29133356

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. https://pubmed.ncbi.nlm.nih.gov/29341841

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. https://pubmed.ncbi.nlm.nih.gov/29357392

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. https://pubmed.ncbi.nlm.nih.gov/29447001

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. https://pubmed.ncbi.nlm.nih.gov/28135725

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. https://pubmed.ncbi.nlm.nih.gov/26551272

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. https://pubmed.ncbi.nlm.nih.gov/29443671

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. https://pubmed.ncbi.nlm.nih.gov/29159416

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. https://pubmed.ncbi.nlm.nih.gov/29710197

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. https://pubmed.ncbi.nlm.nih.gov/29671534

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. https://pubmed.ncbi.nlm.nih.gov/29242891

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. https://pubmed.ncbi.nlm.nih.gov/28057444

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:687-91.

a. Prometheus Laboratories. Trandate tablets prescribing information. San Diego, CA; 2002 Dec.

b. Prometheus Laboratories. Trandate injection prescribing information. San Diego, CA; 2003 Jan.